이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Silence Therapeutics 미래 성장

Future 기준 확인 2/6

Silence Therapeutics 의 수익은 연간 15.3% 감소할 것으로 예상되는 반면, 연간 수익은 29.7% 로 증가할 것으로 예상됩니다. 29.7% 연간. EPS는 연간 14% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -52.6% 로 예상됩니다.

주요 정보

-11.2%

수익 성장률

14.0%

EPS 성장률

Biotechs 수익 성장	24.4%
매출 성장률	29.7%
향후 자기자본 수익률	-52.6%
애널리스트 커버리지	Low
마지막 업데이트	28 Jun 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

OTCPK:SLNC.F - 애널리스트의 미래 추정치 및 과거 재무 데이터 (GBP Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	24	-107	-102	-75	2
12/31/2025	32	-85	-87	-70	5
12/31/2024	27	-41	-56	-42	5
3/31/2024	26	-35	-39	-39	N/A
12/31/2023	25	-43	-39	-39	N/A
9/30/2023	28	-43	-41	-41	N/A
6/30/2023	29	-41	-46	-45	N/A
3/31/2023	23	-43	-39	-39	N/A
12/31/2022	18	-40	-46	-45	N/A
9/30/2022	16	-36	-35	-34	N/A
6/30/2022	16	-39	-31	-30	N/A
3/31/2022	15	-39	3	5	N/A
12/31/2021	12	-39	5	7	N/A
9/30/2021	11	-42	3	4	N/A
6/30/2021	10	-42	2	2	N/A
3/31/2021	8	-35	-24	-23	N/A
12/31/2020	5	-33	-11	-11	N/A
9/30/2020	3	-26	0	1	N/A
6/30/2020	1	-22	12	13	N/A
3/31/2020	1	-21	7	7	N/A
12/31/2019	0	-20	2	2	N/A
9/30/2019	0	-19	-8	-8	N/A
6/30/2019	N/A	-18	-18	-18	N/A
3/31/2019	N/A	-18	-18	-18	N/A
12/31/2018	N/A	-18	-17	-17	N/A
9/30/2018	N/A	-12	-15	-15	N/A
6/30/2018	N/A	-5	-14	-14	N/A
3/31/2018	0	-3	-12	-12	N/A
12/31/2017	0	-2	N/A	-10	N/A
9/30/2017	0	-5	N/A	-9	N/A
6/30/2017	1	-9	N/A	-9	N/A
3/31/2017	1	-9	N/A	-9	N/A
12/31/2016	1	-8	N/A	-10	N/A
9/30/2016	0	-8	N/A	-10	N/A
6/30/2016	N/A	-7	N/A	-9	N/A
3/31/2016	N/A	-7	N/A	-9	N/A
12/31/2015	N/A	-7	N/A	-8	N/A
9/30/2015	0	-8	N/A	-9	N/A
6/30/2015	0	-10	N/A	-9	N/A
3/31/2015	0	-10	N/A	-9	N/A
12/31/2014	0	-11	N/A	-9	N/A
9/30/2014	0	-11	N/A	-9	N/A
6/30/2014	0	-11	N/A	-9	N/A
3/31/2014	0	-10	N/A	-8	N/A
12/31/2013	0	-9	N/A	-7	N/A
9/30/2013	0	-8	N/A	-6	N/A

애널리스트 미래 성장 예측

수입 대 저축률: SLNC.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: SLNC.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: SLNC.F 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: SLNC.F 의 수익(연간 29.7% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: SLNC.F 의 수익(연간 29.7% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: SLNC.F (는) 3년 내에 수익성이 없을 것으로 예상됩니다.

Silence Therapeutics 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Recent updates

Silence Therapeutics plc Announces Positive Results from Ongoing SANRECO Phase 1 Study of Divesiran in Polycythemia Vera Patients

Silence Therapeutics plc Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(A)

Silence Therapeutics plc Announces Retirement of Alistair Gray from Board of Directors, Effective May 1, 2024

Silence Therapeutics plc, Annual General Meeting, May 17, 2024

Silence Therapeutics plc Announces JAMA Publication of Additional Phase 1 Data for Zerlasiran in Subjects with Elevated Lipoprotein(a)

Silence Therapeutics plc Announces Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lipoprotein(A)

Silence Therapeutics plc to Report Q4, 2023 Results on Mar 13, 2024

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics plc Announces Positive Topline Results from Phase 1 Multiple Dose Study of Zerlasiran in Subjects with High Lipoprotein(a) and Stable Atherosclerotic Cardiovascular Disease

Silence Therapeutics plc Announces Retirement of Giles Campion as Chief Medical Officer, Head of Research & Development and Member of Board

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics plc Provides SLN360 and SLN124 Clinical Program Updates

Silence Therapeutics plc Presents New Analysis from SLN360 Phase 1 Single Dose Study in High Lipoprotein(a) at the American Heart Association (AHA) 2022 Annual Meeting

Silence Therapeutics Announces Preliminary Single Dose Results from SLN124 Phase 1 Study in Patients with Thalassemia

Silence Therapeutics plc Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera

Silence Therapeutics plc, Annual General Meeting, Jun 14, 2022

Silence Therapeutics Announces Detailed Results From SLN360 Phase 1 Study in High Lipoprotein(a) Presented in Late Breaker at the American College of Cardiology (ACC.22) Annual Meeting

Silence Therapeutics plc to Report Q4, 2021 Results on Mar 17, 2022

Silence Therapeutics plc Announces Executive Changes

Silence Therapeutics Announces Positive Topline Data in SLN360 Phase 1 Single-Ascending Dose Study in Healthy Adults with High Lipoprotein(a)

Silence Therapeutics plc Presents Additional Positive Data from the SLN124 Healthy Volunteer Study

Silence Therapeutics Updates on AIM Delisting

Silence Therapeutics plc announced that it has received $40 million in funding from AstraZeneca PLC

Silence Therapeutics plc Announces Positive Data from GEMINI Phase 1 Study of SLN124 in Healthy Volunteers

Silence Therapeutics plc to Report Fiscal Year 2020 Results on Mar 30, 2021

Silence Therapeutics plc & Mallinckrodt plc Initiate Work on 3Rd Target

Silence Therapeutics plc announced that it has received $45.499905 million in funding from a group of investors

Silence Therapeutics plc Initiates Dosing in Phase 1 Clinical Trial of Sln360 for Cardiovascular Disease Due to High Lipoprotein(A)

Silence Therapeutics Appoints Michael H. Davidson to Board of Directors

Silence Therapeutics Appoints Craig Tooman as CFO

Silence Therapeutics plc Presents Positive Pre-Clinical Data for SLN360 for the Treatment of Elevated Lipoprotein(a) At American Heart Association 2020

Silence Therapeutics plc Appoints Marie Wikström Lindholm as Senior Vice President, Molecular Design and Member of the Silence Executive Leadership Team

Silence Therapeutics plc Announces Rob Quinn, the Current CFO Will Leave the Company in January 2021

Silence Therapeutics Appoints Mark Rothera as Chief Executive Officer

Silence Therapeutics plc has completed a Follow-on Equity Offering in the amount of $311.826401 million.

Silence Therapeutics plc to Report First Half, 2020 Results on Sep 14, 2020

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견